Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology

Donegani, Maria Isabella; Marra, Stefano; Miceli, Alberto; Raffa, Stefano; Bauckneht, Matteo; Morbelli, Silvia

doi:10.3390/medicina56080373

Cited by 10 publications

(7 citation statements)

References 90 publications

(139 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inflammatory infiltration and related tumor changes can also hamper the FDG PET/CTbased response's reliability. However, several studies have to date suggested a potential added value of this approach, at least in selected patients [24]. In a previous study by our group comparing the first response assessment to Nivolumab using CT and FDG PETbased criteria in the same cohort of patients, FDG imaging maintained a prognostic value even in patients classified as PD based on CT [28].…”

Section: Discussionmentioning

confidence: 90%

“…As the anticancer immune response results from the complex interplay between T cells and other immune cells, peripheral biomarkers increased attention even in the setting of immunotherapy [19][20][21][22]. On the other hand, 18F-fluorodeoxyglucose positron emission tomography (FDG PET/CT) can display the tumor microenvironment's glucose consumption [23][24][25]. Thus, it is reasonable to assume that the combination of FDG PET/CT with systemic inflammation indexes might further improve cancer patients' prognostic stratification.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab

Bauckneht

Genova

Rossi

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

An emerging clinical need is represented by identifying reliable biomarkers able to discriminate between responders and non-responders among patients showing imaging progression during the administration of immune checkpoints inhibitors for advanced non-small cell lung cancer (NSCLC). In the present study, we analyzed the prognostic power of peripheral-blood systemic inflammation indexes and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in this clinical setting. In 45 patients showing radiological progression (defined as RECIST 1.1 progressive disease) during Nivolumab administration, the following lab and imaging parameters were collected: neutrophil-to-lymphocyte ratio (NLR), derived-NLR (dNLR), lymphocyte-to-monocyte ratio (LMR), platelets-to-lymphocyte ratio (PLR), systemic inflammation index (SII), maximum standardized uptake value, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). MTV and SII independently predicted OS. Their combination in the immune metabolic prognostic index (IMPI) allowed the identification of patients who might benefit from immunotherapy continuation, despite radiological progression. The combination of FDG PET/CT volumetric data with SII also approximates the immune-metabolic response with respect to baseline, providing additional independent prognostic insights. In conclusion, the degree of systemic inflammation, the quantification of the metabolically active tumor burden, and their combination might disclose the radiological progression in NSCLC patients receiving Nivolumab.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab

Bauckneht

Genova

Rossi

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Compared with morphologic imaging, [18F]FDG PET/CT images can early detect irAEs due to the increased uptake of [18F]FDG at these sites. This potentially allows for a rapid intervention in life-threatening cases, such as severe colitis, pneumonitis, and pancreatitis [ 127 , 151 ].…”

Section: In Vivo Biomarkers For Immunotherapy: Molecular Imagingmentioning

confidence: 99%

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

Liberini

Mariniello

Righi

et al. 2021

Cancers

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer-related death, and it is usually diagnosed in advanced stages (stage III or IV). Recently, the availability of targeted strategies and of immunotherapy with checkpoint inhibitors (ICI) has favorably changed patient prognosis. Treatment outcome is closely related to tumor biology and interaction with the tumor immune microenvironment (TME). While the response in molecular targeted therapies relies on the presence of specific genetic alterations in tumor cells, accurate ICI biomarkers of response are lacking, and clinical outcome likely depends on multiple factors that are both host and tumor-related. This paper is an overview of the ongoing research on predictive factors both from in vitro/ex vivo analysis (ranging from conventional pathology to molecular biology) and in vivo analysis, where molecular imaging is showing an exponential growth and use due to technological advancements and to the new bioinformatics approaches applied to image analyses that allow the recovery of specific features in specific tumor subclones.

show abstract

“…Finally, the emerging role of immunotherapy and in particular of immune checkpoints inhibitors (ICPIs) in several cancers, including HNC have further stimulated the development of PET-based prognostic biomarkers ( 66 ). RT can modify the expression of some receptor (as PD1/PD-L1) on cancer cells or on myeloid cells, which may affect response to PD-1-based immunotherapy.…”

Section: Role Of Molecular Imaging In Researchmentioning

confidence: 99%

Prediction of Response in Head and Neck Tumor: Focus on Main Hot Topics in Research

2021

View full text Add to dashboard Cite

Radiation therapy is a cornerstone in the treatment of head and neck cancer patients; actually, their management is based on clinical and radiological staging with all patients at the same stage treated in the same way. Recently the increasing knowledge in molecular characterization of head and neck cancer opens the way for a more tailored treatment. Patient outcomes could be improved by a personalized radiotherapy beyond technological and anatomical precision. Several tumor markers are under evaluation to understand their possible prognostic or predictive value. In this paper we discuss those markers specific for evaluate response to radiation therapy in head and neck cancer for a shift toward a biological personalization of radiotherapy.

show abstract

Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology

Cited by 10 publications

References 90 publications

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

Prediction of Response in Head and Neck Tumor: Focus on Main Hot Topics in Research

Contact Info

Product

Resources

About